Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2012

View Archived Issues

Ranbaxy Laboratories presents new MMP-9 inhibitors

Novel anticancer compounds patented by Sanofi

New BTK inhibitor shows promise to treat B-cell malignancies

Advinus Therapeutics discloses new adenosine A2A receptor antagonists

New phase II results on quadruple therapy for treatment-resistant hepatitis C

Investigators in France rediscover traditional antimalarial agent

Astellas and Kaketsuken sign Japanese marketing agreement for vaccine

Novel PI3Kbeta inhibitor shows potential to treat PTEN-deficient tumors

Alder BioPharmaceuticals raises funds to support development of antibody therapeutics

CHMP confirms MAA opinion on Folotyn

Canadian study identifies potential new targets for breast cancer therapy

Novartis announces changes in fingolimod labeling in U.S. and E.U.

Array BioPharma discloses new agents for Alzheimer's disease

Novel products disclosed by Genentech and MRC Technology

Novel LDL-PLA(2) inhibitors patented by GSK

BTG reports outcome of second pivotal Varisolve study

AstraZeneca announces new acquisition plan

MicuRx completes phase I trial of next-generation oral antibiotic

Takeda announces CHMP opinion on Rienso

Japan's MHLW lifts condition on Humira approval

CHMP issues positive opinion on SkyePharma asthma therapy

CHMP recommends approval of Jakavi

European approval of Forxiga recommended

FDA extends review of linaclotide

Japan Tobacco and Torii report topline results from phase III GBA4-1 study

EMA committee maintains recommendation on Glybera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...